VELBAN
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELBAN (vinblastine sulfate) is an injectable small-molecule vinca alkaloid approved in 1965 for anaplastic large cell lymphoma (ALCL). The drug works by disrupting microtubule function in cancer cells, inducing cell cycle arrest and apoptosis. It is administered intravenously and represents a legacy chemotherapy backbone in hematologic malignancies.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and focusing on maintenance of existing market share rather than expansion or growth investments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VELBAN in a LOE-approaching environment offers limited growth but strong operational and relationship management skills in a mature market. Roles focus on stakeholder engagement, access preservation, and niche market maintenance rather than launch or expansion.
Brand ManagerField Sales Representative
Worked on VELBAN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.